Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 alone or with enfortumab vedotin in advanced or metastatic urothelial carcinoma
CTR20262121Phase 2Active
- Sponsor
- Pfizer
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in transitional cell carcinoma (TCC), sponsored by Pfizer. Started Jul 2026; status: active.
02
Drugs
PF-08634404
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20262121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262121.